Faecal Parameters in the Assessment of Activity in Inflammatory Bowel Disease

References

• Brignola C, Lanfranchi GA, Campieri M, et al. Importance of laboratory parameters in the evaluation of Crohn’s disease activity. J Clin Gastroenterol 1986; 8: 245–8.
   PubMed Web of Science ®Google Scholar
• Beck IT. Laboratory assessment of inflammatory bowel disease. Dig Dis Sci 1987; 32 Suppl 12: 26S–41S.
   Google Scholar
• Lobo AJ, Sobala GM, Juby LD, Jones SC, Rathbone BJ, Axon ATR. Evaluation of indices for disease activity in Crohn’s disease by consensus analysis. Eur J Gastroenterol Hepatol 1991; 3: 663–6.
   Web of Science ®Google Scholar
• Tromm A, Tromm CD, Huppe D, Schwegler U, Krieg M, May B. Evaluation of different laboratory tests and activity indices reflecting the inflammatory activity of Crohn’s disease. Scand J Gastroenterol 1992; 27: 774–8.
   PubMed Web of Science ®Google Scholar
• Kieldsen J. Assessment of disease activity in inflammatory bowel disease. Scand J Gastroenterol 1993; 28: 1–9.
   PubMed Web of Science ®Google Scholar
• Cellier C, Sahmoud T, Froguel E, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn’s disease. A prospective multicentre study of 121 cases. Gut 1994; 35: 231–5.
   Google Scholar
• Tromm A, Huppe D, Eckenberg K, Schwegler U, Krieg M, May B. Laboratory tests and activity indices in acute ulcerative colitis with respect to the extent of the disease. Eur J Gastroenterol Hepatol 1993; 5: 21–5.
   Web of Science ®Google Scholar
• Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Final report on a therapeutic trial. Br Med J 1955; 2: 1041–62.
   Web of Science ®Google Scholar
• Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn’s Disease Activity Index (CDAI). Gastroenterology 1979; 77: 843–6.
   Google Scholar
• van Hees PA, van Elteren PH, van Lier HJ, van Tongeren JH. An index of inflammatory activity in patients with Crohn’s disease. Gut 1980; 21: 279–86.
   PubMed Web of Science ®Google Scholar
• Harvey RF, Bradshaw JM. A simple index of Crohn’s disease activity. Lancet 1980; 1: 514.
   PubMed Web of Science ®Google Scholar
• Tongeren JH, van Reichert WJ. Demonstration of protein-losing gastroenteropathy. The quantitative estimation of gastrointestinal protein loss, using 51Cr-labelled plasma proteins. Clin Chim Acta 1966; 14: 42–8.
   Google Scholar
• Beeken WL, Busch HJ, Sylvester DL. Intestinal protein loss in Crohn’s disease. Gastroenterology 1972; 62: 207–15.
   PubMed Web of Science ®Google Scholar
• Nordgren S, Hellberg R, Cederblad A, Fasth S, Lindstedt G, Hulten L. Fecal excretion of radiolabeled (51CrCl3) proteins in patients with Crohn’s disease. Scand J Gastroenterol 1990; 25: 345–51.
   PubMed Web of Science ®Google Scholar
• Crossley JR, Elliott BE. Simple method for diagnosing proteinlosing enteropathy. Br Med J 1977; 1: 428–9.
   PubMed Web of Science ®Google Scholar
• Haeney MR, Fields J, Thompson RA, Asquitt P. Is faecal alpha1-antitrypsin excretion a reliable screening test for proteinlosing enteropathy? Lancet 1978; 2: 1161–2.
   PubMed Web of Science ®Google Scholar
• Bernier JJ, Florent Ch, Desmazurres Ch, Aymes Ch, l’Hirondel ChL. Diagnosis of protein-losing enteropathy by gastrointestinal clearance of alpha1-antitrypsin. Lancet 1978; 2: 760–4.
   Google Scholar
• Keaney NP, Kelleher J. Faecal excretion of alpha1-antitrypsin in protein-losing enteropathy. Lancet 1980; 2: 711.
   Google Scholar
• Florent C, l’Hirondel C, Desmazurres C, Aymes C, Bernier J. Intestinal clearance of alpha1-antitrypsin: a sensitive method for detection of protein-losing enteropathy. Gastroenterology 1981; 81: 777–80.
   Google Scholar
• Hill RE, Hercz A, Corey ML, Hamilton JR. Faecal clearance of alpha1-antitrypsin: a reliable measure of enteric protein loss in children. J Pedriatr 1981; 99: 416–8.
   PubMed Web of Science ®Google Scholar
• Carrell RW. Alpha1-antitrypsin: molecular pathology, leukocytes and tissue damage. J Clin Invest 1986; 78: 1427–31.
   PubMed Web of Science ®Google Scholar
• Perlmutter DH, Daniels JD, Auerbach HS, De Schrijver-Keeskemetti K, Winter HS, Alpers DH. The alpha1-antitrypsin gene is expressed in human epithelial cell line. J Biol Chem 1989; 264: 9485–90.
   Google Scholar
• Bohe M, Genell S, Ohlsson K. Protease inhibitors in plasma and faecal extracts from patients with active inflammatory bowel disease. Scand J Gastroenterol 1986; 21: 598–604.
   Google Scholar
• Wilson CM, McGillagan K, Thomas DW. Determination of fecal alpha1-antitrypsin concentration by radial immunodiffusion: two systems compared. Clin Chim 1988; 34: 372–6.
   Google Scholar
• Lopez A, Hinojosa J, Miralles A, Primo J, Bermudez JD. Fecal excretion of alpha1-antitrypsin in patients with Crohn’s disease. A comparison of nephelometry and radial immunodiffusion. Dig Dis Sci 1994; 39: 507–12.
   Google Scholar
• Brouwer J, Smekens F. Determination of alpha 1-antitrypsin in fecal extracts by enzyme immunoassay. Clin Chim Acta 1990; 189: 173–80.
   PubMed Web of Science ®Google Scholar
• Karbach U, Ewe K, Bodenstein H. Alpha 1-antitrypsin, a reliable endogenous marker for intestinal protein loss and its application in patients with Crohn’s disease. Gut 1983; 24: 718–23.
   Google Scholar
• Meyers S, Wolke A, Field SP, Feuer EJ, Johnson JW, Janowitz HD. Fecal alpha1-antitrypsin measurement: an indicator of Crohn’s disease. Gastroenterology 1985; 89: 13–8.
   PubMed Web of Science ®Google Scholar
• Fischbach W, Becker W, Mossner J, Koch W, Reiners C. Faecal alpha-1-antitrypsin and excretion of 111-Indium granulocytes in assessment of disease activity in chronic inflammatory bowel diseases. Gut 1987; 28: 386–93.
   Google Scholar
• Thomas DW, Sinatra FR, Merritt RJ. Random fecal alpha-1-antitrypsin concentration in children with gastrointestinal disease. Gastroenterology 1981; 80: 776–82.
   Google Scholar
• Crama-Bohbouth G, Pena AS, Biemond I, et al. Are activity indices helpful in assessing active intestinal inflammation in Crohn’s disease? Gut 1989; 30: 1236–40.
   Google Scholar
• Florent C, l’Hirondel ChL, Desmazurres Ch, Giradeaux V, Bernier JJ. Evaluation de l’evolutivite de la maladie de Crohn et de la rectocolite hemorragique par la mesure de la clairance fecale de l’antitrypsine. Gastroenterol Clin Biol 1981; 5: 193–7.
   Google Scholar
• Miura S, Yoshioka M, Tanaka S, et al. Faecal clearance of alpha 1-antitrypsin reflects disease activity and correlates with rapid turnover proteins in chronic inflammatory bowel disease. J Gastroenterol Hepatol 1991; 6: 49–52.
   PubMed Web of Science ®Google Scholar
• Crama-Bohbouth GE, Biemond I, Pena AS, et al. Significance of faecal lysozyme excretion and alpha-1-antitrypsin clearance in the assessment of activity in inflammatory bowel disease. In: Bohbouth GE, editor. Activity related abnormalities in inflammatory bowel disease. Woerden: Huybregts Press, 1998. p. 89–103.
   Google Scholar
• Thomas DW, Sinatra FR, Merritt RJ. Fecal alpha 1-antitrypsin excretion in young people with Crohn’s disease. J Pediatr Gastroenterol Nutr 1983; 2: 491–6.
   Google Scholar
• Grill BB, Hillemeier AC, Gryboski JD. Fecal alpha 1-antitrypsin clearance in patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1984; 3: 56–61.
   Google Scholar
• Arndt B, Schurmann G, Betzler M, Herfarth C, Schmidt-Gayk H. Assessment of Crohn’s disease activity and alpha 1-antitrypsin in faeces. Lancet 1992; 340: 1037.
   Google Scholar
• Kapel N, Meillet D, Magne D, Reighvarg D, Gobert JG. Evaluation of intestinal clearance of alpha1-antitproteinase and immunoglobulins during Crohn’s disease and ulcerative colitis. Eur J Clin Chem Clin Biochem 1992; 30: 197–202.
   PubMedGoogle Scholar
• Karbach U, Ewe K, Dehos H. Antiinflammatory treatment and intestinal alpha 1-antitrypsin clearance in active Crohn’s disease. Dig Dis Sci 1985; 30: 229–35.
   Google Scholar
• Meyers S, Lichtiger S, Feuer EJ, Lahman EA, Janowitz HD. Fecal alpha 1-antitrypsin as a measure of Crohn’s disease activity. The effect of therapy and anatomical extent of disease. J Clin Gastroenterol 1988; 10: 491–7.
   Google Scholar
• Boirivant M, Quintieri F, Pugliese O, Famularo G, Fais S, Pallone F. A limiting-dilution analysis of activated circulating B cells in Crohn’s disease. J Clin Immunol 1990; 10: 128–34.
   PubMed Web of Science ®Google Scholar
• Saitoh O, Matsumoto H, Sugimori K, et al. Intestinal protein loss and bleeding assessed by fecal hemoglobin, transferrin, albumin, and alpha-1-antitrypsin levels in patients with colorectal diseases. Digestion 1995; 56: 67–75.
   PubMed Web of Science ®Google Scholar
• Saverymuttu SH, Peters AM, Crofton ME. Indium autologous granulocytes in the detection of inflammatory bowel disease. Gut 1985; 26: 955–60.
   Google Scholar
• Saverymuttu SH, Camilleri M, Rees H, Levender JP, Hodgson HJF, Chadwick VS. Indium 111-granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease. Gasteroenterology 1986; 90: 1121–8.
   PubMed Web of Science ®Google Scholar
• Geboes K, Van den Oord JJ, Rutgeerts P, Desmet VJ, Vantrappen G. Immunohistochemical identification of lysozyme in pseudopyloric gland metaplasia in Crohn’s disease. Hepato-gastroenterology 1983; 30: 158–60.
   PubMedGoogle Scholar
• Stamp GW, Poulsom R, Chung LP, et al. Lysozyme gene expression in inflammatory bowel disease. Gastroenterology 1992; 103: 532–8.
   PubMed Web of Science ®Google Scholar
• Klass HJ, Neale G. Serum and faecal lysozyme in inflammatory bowel disease. Gut 1978; 19: 233–9.
   PubMed Web of Science ®Google Scholar
• Dick W, Braun OH, Nagel W. Lysozyme in children with acute and chronic inflammatory intestinal diseases. Pediatr Pathol 1985; 20: 143–50.
   Google Scholar
• Hemrika MH, Costongs GM, Engels LG, Bos LP, Janson PC, Flendrig JA. Clinical relevance of lysozyme in the faeces. Neth J Med 1989; 34: 174–81.
   PubMed Web of Science ®Google Scholar
• Sugi K, Saitoh O, Hirata I, Katsu K. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am J Gastroenterol 1996; 91: 927–34.
   PubMed Web of Science ®Google Scholar
• van der Sluys Veer A, Brouwer J, Biemond I, Bohbouth GE, Verspaget HW, Lamers CBHW. Fecal lysozyme in assessment of disease activity in inflammatory bowel disease. Dig Dis Sci 1998; 43: 590–95.
   PubMed Web of Science ®Google Scholar
• Guerrant RL, Araujo V, Soares E, et al. Measurement of fecal lactoferrin as a marker of fecal leukocytes. J Clin Microbiol 1992; 30: 1238–42.
   PubMed Web of Science ®Google Scholar
• Adeyemi EO, Hodgson HJ. Faecal elastase reflects disease activity in active ulcerative colitis. Scand J Gastroenterol 1992; 27: 139–42.
   PubMed Web of Science ®Google Scholar
• Brouwer J. Semiquantitative determination of fecal leukocyte esterase by a dip-and-read assay. Clin Chem 1993; 39: 2531–2.
   PubMed Web of Science ®Google Scholar
• Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992; 339: 89–91.
   Google Scholar